This Week in Hemophilia

Made with ❤️ by Tiago Lopes, PhD, Research Scientist
Nezu Life Sciences, Germany

9. August 2024

Adeno-associated virus (AAV)-based vector integration?
Link: https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(24)00110-4

The study explores how a specific gene therapy vector, derived from Adeno-associated virus serotype 5 (AAV5), interacts with the DNA of host cells over time. This research is crucial because AAV-based gene therapies, such as those used to treat severe hemophilia A, involve inserting new genetic material into patients' cells. Understanding whether this insertion could lead to unintended consequences, like cancer, is essential for ensuring the safety of these treatments.

The researchers conducted their study using a mouse model, focusing on how the AAV5 vector integrates into the DNA of liver cells, where these gene therapies are usually targeted. They used two different production methods for the vector—one from human embryonic kidney cells (HEK293) and another from insect cells (Sf cells)—to see if the source of the vector made a difference in how it behaved in the body. The mice were treated with the vector, and their liver tissues were analyzed at various times up to 57 weeks after treatment.

The main finding was that while most of the vector's genetic material remains separate from the host DNA, a small portion does integrate into the host genome. However, these integrations happened at a low frequency and did not increase over time. Importantly, there was no evidence that these integrations led to harmful effects, such as the uncontrolled cell growth that could lead to tumors.

This study contributes significantly to the broader understanding of hemophilia gene therapy by reinforcing the idea that AAV5-based therapies are generally safe, even over extended periods. The findings suggest that the risk of cancer or other severe side effects from these integrations is low, supporting the continued use and development of gene therapies for hemophilia and potentially other genetic disorders.

Concizumab – A New Therapy for Hemophilias A and B
Link: https://www.rpthjournal.org/article/S2475-0379(24)00165-1/fulltext

The study explored the effects of concizumab, a new treatment designed for people with hemophilia A or B who have developed inhibitors. Inhibitors are antibodies that some patients develop, which make traditional treatments, like factor replacement therapy, less effective. This is a significant issue because it can lead to more frequent and severe bleeding episodes, which greatly impacts patients' quality of life.

To address this, the study tested concizumab, a medication that can be injected under the skin daily. The researchers aimed to see how this treatment affected patients' health-related quality of life, their experience with the treatment, and their preference compared to their previous therapies. They used several questionnaires to gather this information directly from the patients, focusing on aspects like pain, physical functioning, and overall satisfaction with the treatment.

The study involved a phase 3 clinical trial, which is a critical stage where the treatment is tested in larger groups of patients to confirm its effectiveness, monitor side effects, and compare it to standard treatments. Patients were divided into groups, with some receiving concizumab and others not

receiving any prophylaxis (preventative treatment). This comparison allowed the researchers to see if those on concizumab had better outcomes.

The results showed that patients on concizumab reported better quality of life, with fewer bleeding episodes, less pain, and an easier treatment routine compared to their previous experiences. They also expressed a strong preference for concizumab, highlighting its convenience, particularly the less invasive subcutaneous injections, which are easier and less painful than intravenous ones.

These findings are important because they suggest that concizumab could offer a more manageable and effective treatment option for people with hemophilia who have inhibitors, potentially improving their daily lives significantly. The study adds to the growing body of evidence supporting new approaches to managing hemophilia, particularly for those with complex cases involving inhibitors.

New Trials with Efmoroctocog alfa
Link: https://journals.sagepub.com/doi/10.1177/20406207241257917?url_ver=Z39.88-2003

This study investigates the long-term effects of efmoroctocog alfa, a treatment for hemophilia A, on patients' quality of life, focusing on pain, mental, and physical health. Hemophilia A is a genetic disorder where blood doesn't clot properly, leading to frequent bleeding, particularly into the joints, which can cause significant pain, joint damage, and a lower quality of life. This study is important because while many treatments aim to reduce bleeding, the overall well-being of patients, including pain management and quality of life, also needs to be addressed.

The research used data from three clinical trials involving both adults and children with severe hemophilia A. The patients received efmoroctocog alfa as a prophylactic treatment, which means it was given regularly to prevent bleeding episodes rather than treating them after they occurred. The study analyzed patient-reported outcomes over a long period (up to six years), focusing on how patients felt about their pain, physical activities, and overall mental and physical health.

The results showed significant improvements in the patients' perceptions of pain and physical health. For instance, more adults reported having less pain and fewer problems with their usual activities as the study progressed. Children also reported better pain management and high satisfaction with their treatment. These improvements were sustained over several years, indicating that efmoroctocog alfa not only helps reduce bleeding episodes but also enhances the overall quality of life for patients with hemophilia A.

These findings contribute to the broader understanding of hemophilia treatment by highlighting that effective management should not only focus on preventing bleeds but also on improving patients' day-to-day experiences, such as reducing pain and enhancing mental and physical well-being. Long-term use of efmoroctocog alfa appears to be a promising approach for achieving these goals in hemophilia A patients.